Table 2.
Relative diazepam bioavailability after the three treatments
| Parameters |
Geometric means |
Ratiob | P | 90% CI | |
|---|---|---|---|---|---|
| Avizafone | Diazepam | ||||
| Cmax (ng·mL−1) | 223 | 118 | 1.89 | – | 1.53–2.35d |
| AUC0 −t (h ng·mL−1) | 5584 | 5224 | 1.07 | – | 1.01–1.13 |
| tmax (h)a | 0.75 | 1.5 | – | <0.001 | – |
| Parameters |
Geometric means |
Ratioc | P | 90% CI | |
| Avizafone | AIBC | ||||
| Cmax (ng·mL−1) | 223 | 197 | 1.136 | – | 1.043–1.238 |
| AUC0 −t (h ng·mL−1) | 5584 | 5025 | 1.111 | – | 1.075–1.148 |
| tmax (h)a | 0.75 | 1 | – | 0.008 | – |
a
Median.
b
Avizafone/Diazepam.
c
Avizafone/AIBC.
d
Bioequivalence criteria not met.
AIBC, avizafone with atropine–pralidoxime in bi-compartmental auto-injector; AUC, area under the curve; Cmax, maximal concentration; tmax, time to reach maximal concentration.